Status In progress
Process STA
ID number 982

Provisional Schedule

Committee meeting: 1 26 April 2018

Project Team

Project lead Stephanie Yates

Email enquiries


Key events during the development of the guidance:

Date Update
06 November 2017 This appraisal is to be rescheduled to allow the company (Pfizer) additional time to resolve unforeseen issues with their economic modelling. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization.
14 September 2017 Invitation to participate
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance